Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study

被引:3
|
作者
Makita, Kenji [1 ,2 ,3 ,5 ]
Hamamoto, Yasushi [1 ]
Kanzaki, Hiromitsu [1 ]
Nagasaki, Kei [1 ]
Kozuki, Toshiyuki [4 ]
机构
[1] Natl Hosp Org, Dept Radiat Oncol, Shikoku Canc Ctr, Matsuyama, Ehime 7910280, Japan
[2] Ehime Univ, Grad Sch Med, Dept Radiol, Toon, Ehime 7910295, Japan
[3] Ehime Prefectural Cent Hosp, Dept Radiol, Matsuyama, Ehime 7900024, Japan
[4] Natl Hosp Org, Dept Thorac Oncol & Med, Shikoku Canc Ctr, Matsuyama, Ehime 7910280, Japan
[5] Natl Hosp Org, Shikoku Canc Ctr, Dept Radiat Oncol, Kou 160 Minami Umenomoto Machi, Matsuyama, Ehime 7910280, Japan
关键词
bone metastasis; lung cancer; palliative; radiotherapy; local control; TO-LYMPHOCYTE RATIO; RADIATION-THERAPY; SKELETAL METASTASES; ZOLEDRONIC ACID; CHEMOTHERAPY; INFLAMMATION; DENOSUMAB; SURVIVAL;
D O I
10.3892/ol.2023.13889
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone metastasis is common in advanced lung cancer, with the incidence reported to be 30%, and radiotherapy (RT) is used for pain relief from bone metastasis. The present study aimed to identify factors affecting local control (LC) of bone metastasis from lung cancer and to assess the significance of moderate RT dose escalation. This was a retrospective cohort study, where LC of bone metastasis from lung cancer that had received palliative RT was reviewed. LC at RT sites was evaluated with follow-up computed tomography (CT). The influence of treatment-, cancer- and patient-related risk factors for LC was assessed. A total of 317 metastatic lesions in 210 patients with lung cancer were evaluated. The median RT dose (biologically effective dose calculated using an alpha/beta of 10 Gy; BED10) was 39.0 Gy (range, 14.4-50.7 Gy). The median follow-up time for survival and median radiographic follow-up time were 8 (range, 1-127) and 4 (range, 1-124) months, respectively. The 0.5-year overall survival and LC rates were 58.9 and 87.7%, respectively. The local recurrence rate in RT sites was 11.0%, and bone metastatic progression, except in RT sites, was observed in 46.1% at the time of local recurrence or the last follow-up CT of the RT sites. According to multivariate analysis, RT sites, pre-RT neutrophil to lymphocyte ratio (NLR), post-RT non-administration of molecular-targeting agents (MTs), and non-administration of bone modifying agents (BMAs) were significant unfavorable factors for LC of bone metastasis. Moderate RT dose escalation (BED10 >39 Gy) tended to improve the LC of RT sites. In cases without MTs, moderate dose escalation of RT dose improved the LC of RT sites. In conclusion, treatment (post-RT MTs and BMAs), cancer (RT sites) and patient (pre-RT NLR)-related risk factors had a large impact on improving the LC of RT sites. Moderate RT dose escalation seemed to have a small impact on improving the LC of RT sites.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma
    Choi, Seo Hee
    Chang, Jee Suk
    Jeong, Yong Hyu
    Lee, Youngin
    Yun, Mijin
    Seong, Jinsil
    LIVER INTERNATIONAL, 2014, 34 (07) : 1118 - 1125
  • [32] Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy
    Kandaz, Mustafa
    Ertekin, Mustafa Vecdi
    Bilici, Mehmet
    TUMORI, 2012, 98 (04) : 445 - 450
  • [33] RADIOTHERAPY FOR LUNG-CANCER - COMPARISON OF RESULTS 628 PATIENTS TREATED WITH PALLIATIVE AND RADICAL TREATMENT
    TANG, JT
    YAMAZAKI, H
    INOUE, T
    KOIZUMI, M
    KAGAWA, K
    NOSE, T
    MURAYAMA, S
    MORI, M
    TAKEUCHI, E
    ITO, M
    IKEDA, H
    INOUE, T
    CANCER JOURNAL - FRANCE, 1995, 8 (04): : 201 - 205
  • [34] Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study
    Chihiro Kondoh
    Kohei Shitara
    Motoo Nomura
    Daisuke Takahari
    Takashi Ura
    Hiroyuki Tachibana
    Natsuo Tomita
    Takeshi Kodaira
    Kei Muro
    BMC Palliative Care, 14
  • [35] Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
    Kenji Makita
    Yasushi Hamamoto
    Hiromitsu Kanzaki
    Masaaki Kataoka
    Shuhei Yamamoto
    Kei Nagasaki
    Hirofumi Ishikawa
    Noriko Takata
    Shintaro Tsuruoka
    Kotaro Uwatsu
    Teruhito Kido
    Radiation Oncology, 16
  • [36] Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
    Abravan, Azadeh
    Eide, Hanne Astrid
    Helland, Aslaug
    Malinen, Eirik
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 22 : 15 - 21
  • [37] A retrospective quality of life analysis using the lung cancer symptom scale in patients treated with palliative radiotherapy for advanced nonsmall cell lung cancer
    Lutz, ST
    Huang, DT
    Ferguson, CL
    Kavanagh, BD
    Tercilla, OF
    Lu, JD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (01): : 117 - 122
  • [38] Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - A retrospective analysis
    Kong, Pengyu
    Yan, Jinglong
    Liu, Donghui
    Ji, Ye
    Wang, Yufu
    Zhuang, Jinpeng
    Wang, Jincai
    Hu, Xiaowei
    Yue, Xiaolong
    MEDICINE, 2017, 96 (51)
  • [39] Diagnostic and prognostic factors, and two nomograms for endometrial cancer patients with bone metastasis A large cohort retrospective study
    Yang, Fengkai
    Zhao, Ruhan
    Huang, Xiaohui
    Wang, Yucheng
    MEDICINE, 2021, 100 (36) : E27185
  • [40] Salvage Radiotherapy for Solitary Metachronous Bone Metastasis in Patients with Breast Cancer
    Miyata, Mari
    Ohguri, Takayuki
    Yahara, Katsuya
    Yamaguchi, Shinsaku
    Imada, Hajime
    Korogi, Yukunori
    ANTICANCER RESEARCH, 2017, 37 (05) : 2575 - 2579